American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 5, 2003, Pages 403-405

  Hollister, Alan S ^b   Kearns, Gregory L ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CAFFEINE; CENTRAL STIMULANT AGENT; EPHEDRA EXTRACT; EPHEDRINE; NON PRESCRIPTION DRUG;

AGITATION; ALPHA ADRENERGIC STIMULATION; BETA ADRENERGIC STIMULATION; BLADDER EMPTYING; BRONCHODILATING ACTIVITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL GROWTH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG UTILIZATION; ENDOTHELIUM CELL; EPHEDRA; EPHEDRA SINICA; FOOD AND DRUG ADMINISTRATION; GINKGO BILOBA; HEALTH EDUCATION; HEALTH HAZARD; HEART ARRHYTHMIA; HEAT STROKE; HUMAN; HYPERTENSION; INSOMNIA; MANIA; MEDICINAL PLANT; MORTALITY; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SHOCK; SIDE EFFECT; STROKE; SUDDEN DEAFNESS; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; CARDIOVASCULAR DISEASES; DRUG LABELING; DRUGS, NON-PRESCRIPTION; EPHEDRA; EPHEDRINE; HUMANS; NERVOUS SYSTEM DISEASES; PHARMACOLOGY, CLINICAL; SOCIETIES, SCIENTIFIC; UNITED STATES;

EID: 0242382801     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00236-4     Document Type: Note

References (19)

1. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetics drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996. p. 199-248.
2. US Food and Drug Administration. Evidence on the safety and effectiveness of Ephedra: implications for regulation. Available from: URL: http://www.fda.gov/ cder/previous_news.htm. Accessed May 21, 2003.
3. Dietary supplements: uncertainties in analyses underlying FDA's proposed rule on ephedrine alkaloids. Washington: General Accounting Office (US); 1999.
4. Wolfe SM. Ephedra - scientific evidence versus money/politics [editorial]. Science 2003;300:437.
5. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8.
6. Food and Drug Administration (US). HHS acts to reduce potential risks of dietary supplements containing ephedra. Available from: URL: http://www.fda.gov/bbs/topics/ NEWS/2003/NEW00875.html. Accessed April 2, 2003.
7. Nam NH, Kim HM, Bae KH, Ahn BZ. Inhibitory effects of Vietnamese medicinal plants on tube-like formation of human umbilical venous cells. Phytother Res 2003;17: 107-11.
8. Boerth JM, Caley CF. Possible case of mania associated with Ma-Huang. Pharmacotherapy 2003;23:380-3.
9. Schweinfurth J, Pribitkin E. Sudden hearing loss associated with ephedra use. Am J Health Syst Pharm 2003; 60:375-7.
10. Morgenstern LB, Viscoli CM, Kernan WN, Brass LM, Broderick JP, Feldmann E, et al. Use of ephedra-containing products and risk for hemorrhagic stroke. Neurology 2003;60:132-35.
11. Charatan F. Ephedra supplement may have contributed to sportsman's death. BMJ 2003;326:464.
12. Samenuk D, Link MS, Homoud MK, Contreras R, Theohardes TC, Wang PJ, et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12-6.
13. Haller CA, Jacob P, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 2002;71:421-32.
14. Bent S, Tiedt TN, Odden MC, Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;138:468-71.
15. Boozer CM, Nasser JA, Heymsfield SB, Want V, Chen G, Solomon JL. An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial. Int J Obes 2001;25:316-24.
16. Boozer CN, Daly PA, Homel P, Solomon JL, Blanchard D, Nasser JA, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obesity 2002;26:593-604.
17. Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA 2003;289:1537-45.
18. Food and Drug Administration (US), Center for Food Safety and Applied Nutrition. Dietary supplements: ephedrine alkaloids. Available from: URL: http://www. cfsan.fda.gov/~dms/ds-ephed.html. Accessed May 21, 2003.
19. Shekelle P, Hardy M, Morton SC, Maglione M, Suttorp M, Roth E, et al. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects. Evidence Report/Technology Assessment No.: 76. Publication No.: 03-E022. Rockville (MD): Agency for Healthcare Research and Quality; 2003.